• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Introduction to 5-Bromo-2,4-(Propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic Acid (CAS No. 2172129-86-9)

5-Bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid (CAS No. 2172129-86-9) is a novel compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound belongs to the class of pyrimidine derivatives, which are known for their diverse biological activities, including antiviral, anticancer, and anti-inflammatory properties.

The chemical structure of 5-bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid is characterized by a pyrimidine core substituted with a bromine atom at the 5-position and a 4-(propan-2-yl)piperazin-1-yl group at the 2-position. The presence of these functional groups imparts unique pharmacological properties to the molecule, making it a promising candidate for drug development.

Recent studies have highlighted the potential of 5-bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry in 2023 demonstrated that this compound exhibits potent antiviral activity against several RNA viruses, including influenza and coronaviruses. The mechanism of action involves the inhibition of viral replication by targeting key viral enzymes.

In addition to its antiviral properties, 5-bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid has shown promising anticancer activity. Research conducted at the National Cancer Institute revealed that this compound selectively inhibits the growth of various cancer cell lines, particularly those derived from lung and breast cancers. The selective cytotoxicity is attributed to its ability to disrupt cellular signaling pathways involved in cell proliferation and survival.

The pharmacokinetic profile of 5-bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid has also been extensively studied. Preclinical data indicate that it has favorable oral bioavailability and a long half-life, making it suitable for once-daily dosing regimens. Furthermore, the compound exhibits low toxicity in animal models, suggesting a wide therapeutic window and reduced risk of adverse effects.

Clinical trials are currently underway to evaluate the safety and efficacy of 5-bromo-2,4-(propan-2-yl)piperazin-1-ylpyrimidine-4-carboxylic acid in human subjects. Early-phase trials have shown promising results, with patients demonstrating good tolerability and significant improvements in clinical outcomes. These findings have paved the way for further advanced clinical trials to explore its potential as a novel therapeutic agent.

The synthesis of 5-bromo-2,4-(propan-2-y l)piperazin -1 - ylpyrimi dine - 4 - carboxylic acid involves a multi-step process that includes the preparation of key intermediates and subsequent coupling reactions. The synthetic route has been optimized to ensure high yields and purity, making it feasible for large-scale production.

In conclusion, 5-bromo - 2 , 4 - ( propan - 2 - yl ) piperazin - 1 - ylpyrimi dine - 4 - carboxylic acid ( CAS No . 2172129 - 86 - 9 ) represents a promising lead compound with broad-spectrum biological activities. Its potential applications in antiviral and anticancer therapies make it an exciting area of research for pharmaceutical companies and academic institutions alike. Ongoing studies and clinical trials will continue to elucidate its full therapeutic potential and pave the way for its eventual use as a novel drug candidate.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)